Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has been given an average recommendation of “Buy” by the seven ratings firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $6.08.
Several equities research analysts recently commented on DRNA shares. Chardan Capital reaffirmed a “hold” rating on shares of Dicerna Pharmaceuticals in a research report on Monday, August 14th. Zacks Investment Research upgraded shares of Dicerna Pharmaceuticals from a “strong sell” rating to a “buy” rating and set a $6.25 price target on the stock in a research note on Monday, October 23rd. Finally, ValuEngine upgraded shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, July 22nd.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.com-unik.info/2017/10/29/dicerna-pharmaceuticals-inc-drna-receives-consensus-rating-of-buy-from-analysts.html.
Dicerna Pharmaceuticals (NASDAQ:DRNA) traded up 1.78% during trading on Friday, hitting $5.15. 59,585 shares of the stock were exchanged. Dicerna Pharmaceuticals has a 12-month low of $2.42 and a 12-month high of $6.75. The stock has a 50 day moving average price of $5.07 and a 200-day moving average price of $3.73. The firm’s market capitalization is $107.35 million.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings data on Thursday, August 10th. The biopharmaceutical company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.54). The company had revenue of $0.25 million during the quarter, compared to the consensus estimate of $0.08 million. Dicerna Pharmaceuticals had a negative net margin of 8,474.12% and a negative return on equity of 168.65%. The company’s revenue was up 2400.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.75) earnings per share. On average, equities research analysts anticipate that Dicerna Pharmaceuticals will post ($2.70) earnings per share for the current fiscal year.
Hedge funds have recently modified their holdings of the business. Deschutes Portfolio Strategy LLC acquired a new position in shares of Dicerna Pharmaceuticals during the 3rd quarter worth about $575,000. EcoR1 Capital LLC increased its stake in shares of Dicerna Pharmaceuticals by 101.0% during the 2nd quarter. EcoR1 Capital LLC now owns 767,992 shares of the biopharmaceutical company’s stock worth $2,435,000 after purchasing an additional 385,992 shares during the last quarter. Palo Alto Investors LLC increased its stake in shares of Dicerna Pharmaceuticals by 4.0% during the 2nd quarter. Palo Alto Investors LLC now owns 500,913 shares of the biopharmaceutical company’s stock worth $1,588,000 after purchasing an additional 19,394 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Dicerna Pharmaceuticals by 4.5% during the 2nd quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock worth $1,078,000 after purchasing an additional 14,517 shares during the last quarter. Finally, Northern Trust Corp increased its stake in shares of Dicerna Pharmaceuticals by 6.1% during the 2nd quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 2,094 shares during the last quarter. Hedge funds and other institutional investors own 55.46% of the company’s stock.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
What are top analysts saying about Dicerna Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Dicerna Pharmaceuticals Inc. and related companies.